Activation of the PI3K/AKT pathway, which is downstream of all of these signaling molecules, is observed in up to 80% of AML cases[5], making this pathway an attractive therapeutic target for more universal therapeutics. This evidence concerns the gene PIK3CA and acute myeloid leukemia.